Oragenics, Inc. (OGEN)
After hours:
| Previous close | 1.6400 |
| Open | 1.6000 |
| Bid | 2.2800 x 1400 |
| Ask | 2.3800 x 1300 |
| Day's range | 1.6000 - 2.4000 |
| 52-week range | 1.0000 - 7.7400 |
| Volume | |
| Avg. volume | 117,217 |
| Market cap | 10.44M |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET. The discussion will address the unmet medical need in Traumatic Brain Injury (TBI), commonly known as concussion, explore common causes, and examine its association with other long-term neu
- GlobeNewswire
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
SARASOTA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced an update on the company and its drug development program. Oragenics is designing an upcoming Phase II clinical trial conducted in acute and emergency departments. The company is preparing to initiate a Phase II clinical trial for its lead drug candidate, ONP-002, an innovative neurosteroid de
- GlobeNewswire
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia. This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion. ONP-002, a novel chemical entity
